| 前收市價 | 1.2300 |
| 開市 | 1.4000 |
| 買盤 | 1.0000 |
| 賣出價 | 1.4500 |
| 拍板 | 3.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 1.4000 - 1.4000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 253 |
ZacksAvidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
ZacksFDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
- Zacks
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
